|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
ZA914750B
(en)
|
1990-06-20 |
1992-03-25 |
Bristol Myers Squibb Co |
Methods of modulating blood pressure using tgf-beta and antagonists thereof
|
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
|
JP4124815B2
(ja)
|
1991-10-31 |
2008-07-23 |
ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ |
ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
|
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
|
US5543143A
(en)
|
1992-03-06 |
1996-08-06 |
Corixa Corporation |
Method for activating macrophages/monocytes
|
|
CA2146973C
(en)
|
1992-10-29 |
2008-09-02 |
Patricia R. Segarini |
Uses of tgf-.beta. receptor fragment as a therapeutic agent
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
DE69434934D1
(de)
|
1993-10-14 |
2007-04-12 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
|
US5470952A
(en)
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
US5866323A
(en)
|
1995-04-07 |
1999-02-02 |
Case Western Reserve University |
Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
|
|
DE69636866D1
(en)
|
1995-04-11 |
2007-03-15 |
Gen Hospital Corp |
Reverse "two-hybrid"-systeme
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
JP2001515360A
(ja)
|
1997-04-18 |
2001-09-18 |
バイオジェン，インコーポレイテッド |
▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
ZA988461B
(en)
|
1997-09-18 |
1999-03-30 |
Idec Pharma Corp |
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
CA2330939A1
(en)
|
1998-06-16 |
1999-12-23 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
|
ES2146552B1
(es)
|
1998-11-24 |
2001-04-16 |
Inst Cientifico Tecnol Navarra |
Peptidos inhibidores de tgf/31
|
|
WO2001066140A1
(en)
|
2000-03-09 |
2001-09-13 |
Genzyme Corporation |
Use of tgf-beta antagonists to treat or to prevent loss of renal function
|
|
AU2001249446A1
(en)
|
2000-03-24 |
2001-10-08 |
Dzgenes, L.L.C. |
Diagnostic polymorphisms of tgf-beta-rii promoter
|
|
US20030028905A1
(en)
|
2001-07-31 |
2003-02-06 |
Petra Knaus |
Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
|
|
AU2003209308A1
(en)
|
2002-01-22 |
2003-09-02 |
Genzyme Corporation |
Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
|
|
US7919084B2
(en)
|
2002-06-17 |
2011-04-05 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
|
CA2513086A1
(en)
|
2002-12-19 |
2004-07-08 |
Scios Inc. |
Treatment of obesity and associated conditions with tgf-.beta. inhibitors
|
|
EP1620128A1
(en)
|
2003-04-30 |
2006-02-01 |
Genzyme Corporation |
Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20060229266A1
(en)
|
2003-08-13 |
2006-10-12 |
Kumar Nalin M |
Silencing of tgf-beta receptor type II expression by sirna
|
|
CA2536293A1
(en)
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
WO2005113585A2
(en)
|
2004-05-20 |
2005-12-01 |
Acceleron Pharma Inc. |
Modified tgf-beta superfamily polypeptides
|
|
US7786261B2
(en)
|
2004-09-02 |
2010-08-31 |
National Research Council Of Canada |
Coiled-coil fusion proteins comprising cell receptor domains
|
|
CN101084007A
(zh)
|
2004-09-22 |
2007-12-05 |
金齐姆公司 |
TGF－β拮抗剂限制免疫抑制剂肾毒性的用途
|
|
US7795389B2
(en)
|
2004-09-28 |
2010-09-14 |
The Board Of Regents Of The University Of Texas System |
Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
|
|
JP5481028B2
(ja)
|
2004-10-13 |
2014-04-23 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
ウイルス関連リンパ増殖性障害を処置または予防するための方法
|
|
WO2006086469A2
(en)
|
2005-02-08 |
2006-08-17 |
Genzyme Corporation |
Antibodies to tgfbeta
|
|
JP5342834B2
(ja)
|
2008-09-05 |
2013-11-13 |
日東電工株式会社 |
骨髄線維症処置剤
|
|
ITMI20060181A1
(it)
|
2006-02-03 |
2007-08-04 |
Univ Padova |
Modulatori del tgf-b e loro uso
|
|
US8454952B2
(en)
|
2006-03-13 |
2013-06-04 |
The Johns Hopkins University |
Augmentation of endothelial thromboresistance
|
|
EP2029625A2
(en)
|
2006-06-05 |
2009-03-04 |
Novartis AG |
Use of tgf-beta antagonists in treatment of parathyroid-related disorders
|
|
DK2083863T3
(da)
|
2006-10-03 |
2015-06-22 |
Genzyme Corp |
Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
|
|
ES2449753T3
(es)
|
2007-03-19 |
2014-03-21 |
National Research Council Of Canada |
Proteínas de fusión que comprenden dos dominios de unión tgf-beta
|
|
EP2171062A1
(en)
|
2007-06-15 |
2010-04-07 |
Genzyme Corporation |
Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
|
|
CA2697077C
(en)
|
2007-08-22 |
2012-10-16 |
Irm Llc |
2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
|
|
WO2009092087A2
(en)
|
2008-01-18 |
2009-07-23 |
The Brigham And Women's Hospital, Inc. |
Selective differentiation, identification, and modulation of human th17 cells
|
|
WO2009143309A2
(en)
|
2008-05-21 |
2009-11-26 |
Trustees Of Dartmouth College |
Female reproductive tract and anal prophylaxes
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
NZ590667A
(en)
|
2008-07-02 |
2013-01-25 |
Emergent Product Dev Seattle |
Tgf-b antagonist multi-target binding proteins
|
|
EP2326670A4
(en)
|
2008-09-17 |
2014-04-16 |
Nat Res Council Canada |
HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
|
|
WO2010048273A2
(en)
|
2008-10-21 |
2010-04-29 |
President And Fellows Of Harvard College |
Methods and compounds for treatment of neurodegenerative disorders
|
|
US8138142B2
(en)
|
2009-01-13 |
2012-03-20 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin in a patient in need thereof
|
|
WO2010129515A1
(en)
|
2009-05-08 |
2010-11-11 |
The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services |
Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma
|
|
WO2011088148A1
(en)
|
2010-01-12 |
2011-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of transforming growth factor-beta 1 expression
|
|
CA3083324A1
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
CN101852804B
(zh)
|
2010-03-29 |
2013-06-12 |
中国医学科学院病原生物学研究所 |
Gdf15蛋白的抗体的新用途
|
|
US8080568B1
(en)
|
2010-06-29 |
2011-12-20 |
Ewha University - Industry Collaboration Foundation |
2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
|
|
MY165160A
(en)
|
2010-09-01 |
2018-02-28 |
Genzyme Corp |
TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
|
|
US20130287688A1
(en)
|
2010-11-18 |
2013-10-31 |
Xtuit Pharmaceuticals, Inc. |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
|
US8800906B2
(en)
|
2010-12-27 |
2014-08-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
|
|
JP6062375B2
(ja)
|
2011-01-06 |
2017-01-18 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
|
|
CN105884900A
(zh)
*
|
2011-04-19 |
2016-08-24 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
|
DK2699590T3
(en)
|
2011-04-20 |
2019-05-06 |
Acceleron Pharma Inc |
ENDOGLIN POLYPEPTIDES AND APPLICATIONS THEREOF
|
|
CN102850458B
(zh)
|
2011-06-28 |
2014-10-01 |
华博生物医药技术（上海）有限公司 |
新型重组双功能融合蛋白及其制法和用途
|
|
WO2013012648A1
(en)
|
2011-07-15 |
2013-01-24 |
Emory University |
Gdf15 in diagnostic and therapeutic applications
|
|
EP2739645B1
(en)
|
2011-08-01 |
2018-12-19 |
Tufts Medical Center, Inc. |
Endoglin-specific antibody for use in a method of treating heart failure and related conditions
|
|
WO2013059879A1
(en)
|
2011-10-26 |
2013-05-02 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Compositions and methods for the treatment of fibrosis and fibrotic diseases
|
|
CN110563850A
(zh)
|
2012-04-30 |
2019-12-13 |
比奥孔有限公司 |
靶向/免疫调节性融合蛋白及其制造方法
|
|
US20150080320A1
(en)
|
2012-05-16 |
2015-03-19 |
Aadigen, Llc |
Multi-target modulation for treating fibrosis and inflammatory conditions
|
|
PT2971048T
(pt)
|
2013-03-11 |
2019-02-06 |
Genzyme Corp |
Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
|
|
CA3081073C
(en)
|
2013-03-12 |
2023-09-12 |
Biocon Ltd. |
Fusion immunomodulatory proteins and methods for making same
|
|
CA2909701C
(en)
|
2013-04-17 |
2022-12-06 |
Baylor College Of Medicine |
Immunosuppressive tgf-.beta. signal converter
|
|
CA2921805C
(en)
|
2013-08-22 |
2023-03-07 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
|
WO2015077540A2
(en)
|
2013-11-21 |
2015-05-28 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
US9676863B2
(en)
|
2014-02-10 |
2017-06-13 |
Merck Patent Gmbh |
Targeted TGFβ inhibitors
|
|
CA2949083C
(en)
|
2014-05-18 |
2023-10-10 |
Children's Medical Center Corporation |
Methods and compositions relating to exosomes
|
|
CN106413740A
(zh)
|
2014-06-13 |
2017-02-15 |
诺华股份有限公司 |
用于降低gdf‑15的serelaxin应用
|
|
CN106794233B
(zh)
|
2014-08-01 |
2021-11-12 |
布里格姆及妇女医院股份有限公司 |
与肺动脉高压的治疗有关的组合物和方法
|
|
JP6631865B2
(ja)
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
US10227392B2
(en)
|
2015-04-06 |
2019-03-12 |
Acceleron Pharma Inc. |
ALK7:ActRIIB heteromultimers and uses thereof
|
|
CN107849114B
(zh)
*
|
2015-04-06 |
2021-08-20 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
HK1256638A1
(zh)
|
2015-08-04 |
2019-09-27 |
Acceleron Pharma Inc. |
用於治疗骨髓增生性病症的方法
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
EP3497130B1
(en)
|
2016-08-12 |
2021-10-27 |
Merck Patent GmbH |
Combination therapy for cancer
|
|
CN118307682A
(zh)
*
|
2016-09-27 |
2024-07-09 |
埃皮辛特瑞柯斯公司 |
免疫调节性融合蛋白
|
|
WO2018129331A1
(en)
|
2017-01-07 |
2018-07-12 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted tgf-b inhibition
|
|
CN118255902A
(zh)
|
2017-03-02 |
2024-06-28 |
加拿大国家研究委员会 |
TGF-β受体胞外域融合分子及其用途
|
|
LT3628049T
(lt)
|
2017-05-04 |
2023-08-25 |
Acceleron Pharma Inc. |
Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
|
|
EP3749682B1
(en)
|
2018-02-09 |
2025-09-24 |
Acceleron Pharma Inc. |
Treating heterotopic ossification
|